[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553107":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":25,"responsibleParty":42,"collaborators":25,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":25,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":25,"overallStatus":64,"whyStopped":25,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":25},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vonorasan fumarate","EXPERIMENTAL","Vonorasan fumarate, 20 mg twice daily orally before meals for 8 weeks of treatment.",[13],"Drug: Vonorasan Fumarate",{"label":15,"type":10,"description":16,"interventionNames":17},"Zuojin Pills combined with Vonorasan Fumarate","Add Zuojin Pills, 3g each time, twice daily, on top of Vonorasan Fumarate treatment for 8 weeks.",[13,18],"Drug: Zuojin Pills",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Vonorasan Fumarate","Vonorasan fumarate is taken 30min before breakfast and dinner.",[9,15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Zuojin Pills","Zuojin Pills should be taken 30min after breakfast and dinner.",[15],[31],{"name":32,"affiliation":33,"role":34},"wanli liu","The First Affiliated Hospital with Nanjing Medical University","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"yan wang","CONTACT","19801295220","292615568@qq.com",{"name":32,"role":38,"phone":25,"phoneExt":25,"email":25},{"type":43,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100553107","zuojin-wan-combined-with-woonosan-fumarate-for-the-treatment-of-grd-combined-with-depression-100553107",false,"NCT06481787","Zuojin Wan Combined With Woonosan Fumarate for the Treatment of GRD Combined With Depression","A Single-centre Randomised Controlled Study of 8-week Zuojinwan in Combination With Volnoxan Fumarate for the Treatment of Gastro-oesophageal Reflux Disease Combined With Depression","Inclusion Criteria:\n\n1. Aged between 18 and 65 years;\n2. Fulfilment of western medical diagnostic criteria for GERD;\n3. Meet the diagnostic criteria for mild depression;\n4. Comply with the diagnostic criteria of Liver and Stomach Depression-Heat syndrome in Chinese medicine;\n5. A score of 7-17 on the 17-item Hamilton Depression Scale (HAMD-17) (7-17 being mild depression);\n6. Good compliance and autonomous behaviour;\n7. No medications that may have an effect on the study, such as acid-suppressing agonists, were taken within 2 weeks prior to enrolment;\n\nExclusion Criteria:\n\n1. HP positive patients;\n2. Other organic diseases of the digestive system, such as peptic ulcer, peptic tumour, peptic haemorrhage, liver, gallbladder and pancreas disease, intestinal obstruction and inflammatory bowel disease;\n3. Systemic diseases affecting the dynamics of the digestive tract, such as diabetes mellitus, chronic renal insufficiency, connective tissue diseases, neurological lesions, etc;\n4. Pathological diagnosis of the esophageal mucosa suggestive of moderate-to-severe heterogeneous hyperplasia;\n5. Previous surgery resulting in a decrease in gastric acid or a history of oesophageal or gastric surgery;\n6. Varicose veins in the esophagus or fundus of the stomach;\n7. Persons with severe primary heart, brain, liver, lung, kidney, blood or serious disease affecting their survival;\n8. Those with depression, suicidal tendencies and mental disorders who cannot cooperate;\n9. Pregnant or breastfeeding women, or patients who have a plan to have children in the near future;\n10. Taking drugs that have an effect on the results of this study within 2 weeks before participating in this study;\n11. Allergy or adverse reaction to the study drug.","ALL","18 Years","65 Years",{"count":55,"type":56},300,"ESTIMATED","INTERVENTIONAL",[59],"NA","To evaluate the improvement of symptoms in patients with gastroesophageal reflux disease combined with depression (hepatic and gastric depression-heat type) by Zuojin Wan combined with vornodine fumarate regimen as a control, and to compare the adherence to the medication and the adverse reactions of the patients between the two groups.",[62,63],"Gastroesophageal Reflux Disease","Depression","NOT_YET_RECRUITING","2024-06-28",{"date":67,"type":68},"2024-07-01","ACTUAL",{"date":70,"type":56},"2024-06-30",{"date":72,"type":56},"2026-06-30",{"name":5,"class":6}]